Tesamorelin: Complete Profile, Uses, Dosage, Benefits and Side-effects
Table of Content
Tesamorelin is a growth hormone-releasing factor (GRF) like the one ordinarily secreted by the brain's hypothalamus gland. Its is synthesized and consists of 44 amino acids from the human GRF. Tesamorelin causes the pituitary gland to produce more growth hormone (GH).
It is used in people infected with the human immunodeficiency virus (HIV) to remove excess fat (lipodystrophy) in the belly or stomach. Lipodystrophy is another name for this disorder. Some HIV patients develop extra belly fat, which may be due to insufficient growth hormone levels. Tesamorelin can help you lose belly fat by increasing the quantity of growth hormones in your body.
Tesamorelin is not a weight-loss medication and should not be used to treat obesity.
(Single Letter): Unk-Tyr-Ala-Asp-Ala-lle-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-
Tesamorelin promotes the generation and release of the endogenous hormone (hGRF) by acting on the brain's pituitary cells. Tesamorelin treatment predisposes the patient to glucose intolerance and increases the risk of type 2 diabetes. Hence it is not recommended during pregnancy.
Tesamorelin is administered through subcutaneous injection. You may be shown how to inject yourself at home. If you do not completely understand how to give the injection and correctly dispose of spent needles and syringes, do not self-inject this drug. This drug comes with injectable instructions to ensure safe and successful administration. Follow these instructions exactly. If you have any questions, see your doctor or chemist.
Tesamorelin is a powder that must be combined with a liquid (diluent) before use. If you use the injections at home, properly mix and store the medication. Only prepare your dosage in a syringe when ready to inject yourself. If the drug has changed colors or contains particles, do not use it. Request a fresh prescription from your doctor. Tesamorelin must be used immediately after being diluted with a diluent. Don't save the mixture for later. Tesamorelin is typically administered once per day. Pay close attention to your doctor's dosage recommendations.
Each time you administer the injection, choose a different location on your stomach. Your doctor will show you the ideal spots to inject the drug into your body. Do not inject at the same location twice in a row. Never share a Tesamorelin syringe with another individual, even if you replace the needle. Sharing syringes or needles allows HIV or other infections to spread from person to person. Your blood will need to be checked often to ensure that this drug is addressing your illness and not producing side effects. Do not skip any follow-up appointments with your doctor. Refrigerate Tesamorelin powder vials rather than freezing them. The diluent should be stored at room temperature, free from moisture, heat, and light. After the expiration date on the label has passed, discard any unused vials.
Once within the human body, Tesamorelin binds to GHRH receptors, stimulating the pituitary gland to release growth hormone at the same rate as the body's naturally occurring GHRH in circulation. When more growth hormones are produced, metabolism and muscle growth improve, allowing you to burn more calories and lose body fat. The peptide can also assist in raising insulin growth factor (IGF-1) levels, which can aid in reducing glucose levels and accelerate weight loss even more. As a result, Tesamorelin can aid in reducing visceral adipose tissue, resulting in a better belly look, size, and waist circumference.
Increased Growth Hormone (GH) Levels
Tesamorelin's primary purpose is to elevate growth hormone (GH) levels, which can have various positive effects on the body.
Reduction of Lipodystrophy Symptoms
Lipodystrophy, a common symptom of HIV and antiretroviral medication, involves abnormal fat distribution in the body. Tesamorelin therapy has significantly reduced visceral adipose tissue (VAT) and improved body composition measures, such as trunk fat, waist circumference, and waist-to-hip ratio.
Lowered Risk of Cardiovascular Diseases
By reducing carotid-intima media size (cIMT), Tesamorelin helps inhibit the progression of carotid atherosclerotic vascular disease. These potential benefits suggest a potential link between Tesamorelin therapy and a decreased risk of developing cardiovascular diseases.
Increased Insulin-like Growth Factor 1 (IGF-1) Levels
Patients with lipodystrophy often have lower levels of IGF-1. Tesamorelin administration stimulates the production of IGF-1, which promotes growth and inhibits programmed cell death without affecting blood glucose levels.
Improved Lipid Profiles
Tesamorelin facilitates the process of lipolysis, leading to reduced cholesterol and triglyceride levels. As a result, lipid profiles are improved in individuals who receive Tesamorelin therapy.
Enhanced Cognitive Capacities: Tesamorelin has been observed to enhance cognitive capacities in individuals over 60. It achieves this by reducing myoinositol (MI), an osmolyte associated with the early onset of Alzheimer's disease.
Tesamorelin side effects often reported include:
- Infection at the injection site
- Erythema at the injection site
- Bruising at the injection site
- Irritation at the injection site
- Discomfort at the injection site
- Other negative effects include leg discomfort, myalgia, peripheral edema, and impaired glucose tolerance.
Serious side effects of Tesamorelin
Tesamorelin may have certain undesired side effects in addition to its necessary functions. Although not all of these adverse effects are likely to occur, they may necessitate medical treatment if they do.
Consult your doctor right away if you experience any of the following negative effects while taking Tesamorelin:
• Difficulty moving
• Muscle pain or stiffness
• Pain in the arms or legs
• Joint pain
• Blurred vision
• burning, crawling, itching, numbness, prickling, "pins and needles," or tingling feelings
• burning, numbness, pain, or tingling in all fingers except the smallest finger
• chest pain
• fast, irregular, pounding, or racing heartbeat or pulse
• pounding in the ears
• slow or fast heartbeat
• swelling of the joints
Other side effects of Tesamorelin
Tesamorelin may cause several side effects that may not require medical treatment. These adverse effects may subside as your body responds to the medication.
Bleeding, blistering, burning, freezing, skin discoloration, pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
• An acidic or sour stomach
• bone ache
• sensation of warmth
• sadness or emptiness
• itchy skin
• lack of appetite
• loss of interest or pleasure
• muscular spasms
• night sweats
• redness of the face, neck, arms, and occasionally the upper chest
• joint stiffness
• stomach discomfort, upset, or pain
• muscle strain
• sudden sweating
• difficulty concentrating
• difficulty sleeping
• inability to sleep
Adult Dosage for Lipodystrophy:
• 1 mg vial: 2 mg once a day.
• 2 mg vial: 1.4 mg once each day.
1.4 mg subcutaneous injection once daily for the 2 mg/vial formulation (Egrifta SV); 2 mg subcutaneous injection once daily for the 1 mg/vial formulation (Egrifta).
Sixty-five years: 1.4 mg subcutaneous injection per day for the 2 mg/vial formulation (Egrifta SV); 2 mg subcutaneous injection per day for the 1 mg/vial formulation (Egrifta).
Keep away from light and in the original container until ready to use. Do not refrigerate or freeze the reconstituted solution once it has been made. If not used promptly, discard.
• 1 mg vial: Refrigerate intact vials at 2°C to 8°C (36°F to 46°F). Keep away from light and in the original container until ready to use. The store provided diluent (SWFI), syringes, and needles at temperatures ranging from 20°C to 25°C (68°F to 77°F). Do not refrigerate or freeze the reconstituted solution once it has been made. If not used promptly, discard.
• 2 mg vial: Store undamaged vials at 25°C (77°F); excursions to 15°C to 30°C (59°F to 86°F) are acceptable. Keep away from light and in the original container until ready to use. The store provided diluent (SWFI), syringes, and needles at temperatures ranging from 20°C to 25°C (68°F to 77°F). Do not refrigerate or freeze the reconstituted solution once it has been made. If not used promptly, discard.
- Cortisone: Tesamorelin may reduce serum concentrations of Cortisone's active metabolite(s). Consider modifying your treatment.
- Macimorelin: Growth Hormone Products may reduce Macimorelin's diagnostic impact. Avoid combining.
- Prednisone: Tesamorelin may reduce serum concentrations of Prednisone's active metabolite(s). Consider modifying your treatment.
In healthy individuals, a single dosage of the 2 mg/vial (Egrifta SV) formulation has an elimination half-life of 8 minutes. After 14 days of therapy, the mean elimination half-life of the 1 mg/vial (Egrifta) formulation in healthy volunteers is 26 minutes.
Tesamorelin, a Growth Hormone Releasing Hormone analog, acts by increasing the levels of Insulin-Like Growth Factor-1 (IGF-1) by promoting the release of Growth Hormone. IGF-1 is responsible for mediating the unique advantages associated with bodybuilding.
According to research, IGF-1 increases muscle growth via satellite cells, reduces muscle breakdown, and inhibits toxin-induced muscle inflammation. When utilizing Tesamorelin for bodybuilding, 1 mg of injection 90 minutes before eating is recommended. You can utilize it for five days straight, then rest for two days before restarting the cycle.
Tesamorelin has the potential to damage an unborn fetus or cause birth abnormalities. If you are pregnant, do not use it. Tesamorelin should not be used if you are allergic to it or have a history of pituitary gland tumor or surgery, a history of head injury or radiation therapy.
Tell your doctor if you have heart disease, high blood pressure, kidney disease, diabetes, epilepsy, asthma, migraines, an adrenal gland issue, or if you have ever had cancer, any form of tumor, or open-heart surgery before using Tesamorelin.
Inform your doctor of significant illnesses, recent trauma, or medical emergencies.